The deal size was increased to $400M in common stock from $250M in common stock. SVB Securities, Guggenheim, Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
- MoonLake Immunotherapeutics price target raised to $61 from $33 at Wedbush
- MoonLake Immunotherapeutics price target raised to $68 from $36 at BTIG
- MoonLake Immunotherapeutics price target raised to $41 from $28 at Barclays
- MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering